We are recruiting participants with Crohn’s disease for a clinical trial to test a potential new treatment.

A new clinical trial for ulcerative colitis accepting participants to study QBECO SSI treatment.

A total of 122 patients have received QBECO SSI treatment. Learn more about the safety and effectiveness to date.

  • Very good safety profile to date
  • 10 people with Crohn's disease were treated through a compassionate use program
  • 7 of the 10 had clinical remission
  • 4 have had sustained clinical remission after discontinuing all treatments
  • The longest case of remission is ongoing after nearly 3 years

Investigational treatment for Crohn’s Disease and Ulcerative Colitis

Our clinical trials involve Site Specific Immunomodulators (SSIs), a novel class of immunotherapy treatment. SSIs are being developed to stimulate the immune system in a targeted manner to reverse the chronic inflammation underlying many conditions, such as Crohn’s disease and ulcerative colitis.

A Phase 2a open label clinical trial for ulcerative colitis to study QBECO SSI treatment is now accepting participants. This study is open to Canadian residents.

Enrollment into the Crohn's disease clinical trial has completed and we are no longer accepting new participants. If you are interested in receiving updates about a future clinical trial in Crohn’s disease involving Qu Biologics’ Site Specific Immunomodulators (SSIs), please email qucrohnstrial@qubiologics.com indicating your request.

Listen to an interview with Dr. Hal Gunn